ConvaTec Group Plc stock faces pressure amid advanced wound care slowdown and US market challenges

ConvaTec Group Plc, a global medical products company focused on advanced wound care, ostomy care, continence care, and infusion care, released its full-year 2025 results on March 5, 2026. The London Stock Exchange-listed firm, trading under ISIN GB00BD3VFW73 in GBP, reported underlying revenue growth of 4.7% at constant exchange rates, slightly missing consensus expectations of around 5%. Advanced wound care, which accounts for over 40% of group revenue, grew just 1.9%, hampered by softer US demand and inventory adjustments at key distributors. This triggered a 5% drop in the ConvaTec Group Plc stock on the LSE in GBP on the day of release, with shares last seen trading around 220p.

As of: 26.03.2026

Dr. Elena Marquez, Senior Healthcare Analyst specializing in medtech supply chains and chronic care devices: In a market favoring high-margin consumables, ConvaTec's wound care stall signals caution for US investors eyeing demographic tailwinds in aging populations.

Full-Year Results Miss Fuels Share Price Reaction

ConvaTec's 2025 performance showed resilience in core segments but exposed cracks in its largest division. Group underlying revenue reached £2.07 billion, up 4.7% on a constant currency basis, driven by 6.3% organic growth partially offset by 1.6% FX headwinds. Operating profit rose 8.2% to £395 million, with margins expanding 110 basis points to 26.1%, aided by mix improvements and cost discipline.

However, advanced wound care faltered with 1.9% growth, down from double-digits in prior years. US sales, contributing over 50% to this segment, faced distributor destocking and slower hospital adoption of new AQUACEL foam dressings. Ostomy care delivered 5.8% growth, fueled by market share gains in the US via the Esteem Body one-piece pouch. Infusion care surged 38%, propelled by 360° Oscillating Pump adoption in diabetes management, though from a smaller base.

The ConvaTec Group Plc stock on the LSE in GBP shed 5.2% on March 5, closing at 221.5p after peaking near 235p pre-results. Trading volume spiked 3x average, reflecting institutional repositioning. Since then, shares have stabilized around 218-225p range on the LSE in GBP as of March 26, 2026.

2026 Guidance Signals Cautious Outlook

Management guided underlying revenue growth of 4-5% for 2026 at constant rates, implying around £2.16-2.18 billion. Advanced wound care is projected at 3-4% growth, with US recovery expected in H2 via new product launches like next-gen hydrofiber technology. Ostomy remains at 5-6%, infusion care 25-30% as pump volumes ramp.

Margin guidance of 26.5% assumes continued productivity savings of £25 million annually, offsetting input cost inflation in polymers and gels. Free cash flow is targeted at £325 million, supporting the progressive dividend policy with a final 2025 payout of 10.61p per share, lifting full-year to 16.52p, up 5.1%.

Analysts note the guidance embeds conservatism, with consensus revenue forecast trimmed to 4.6% from 5.2% post-results. JPMorgan cut its price target to 275p from 290p, maintaining overweight, citing US wound care normalization after pandemic stockpiling. The ConvaTec Group Plc stock trades at 17.5x forward earnings on the LSE in GBP, below medtech peer average of 20x.

US Market Dynamics Drive Investor Focus

For US investors, ConvaTec's exposure is pivotal, with North America generating 52% of 2025 revenue, primarily from advanced wound care and ostomy. US hospitals, facing budget pressures post-COVID, delayed adoption of premium dressings amid reimbursement scrutiny from CMS. Distributor inventory corrections, estimated at 2-3 months' supply, shaved 200 basis points off growth.

Yet tailwinds persist. The US wound care market, valued at $8 billion annually, grows 5% yearly driven by diabetes and obesity epidemics. ConvaTec holds 15% share in hydrocolloid dressings, bolstered by recent FDA clearance for AQUACEL Ag+ Extra, which showed 20% faster healing in trials. Ostomy benefits from Medicare Advantage expansion, increasing patient access to high-end pouches.

Infusion care gains traction with US endocrinologists prescribing the 360 pump for type 2 diabetes, capturing 8% market share in ambulatory settings. US investors should monitor Q1 trading update in May for distributor restocking signals, as this segment's recovery could lift group multiples.

Segment Deep Dive: Wound Care Weakness Explained

Advanced wound care's slowdown stems from multiple factors. Post-pandemic, US acute care facilities normalized inventory after overstocking during 2023-2024 surge cases. Competitive pressure from 3M's next-gen foams and Smith & Nephew's negative pressure devices eroded pricing power, with ConvaTec's average selling price flat year-over-year.

Internationally, China volumes dipped on hospital procurement delays, while Europe held steady at 4% growth. Management's H2 rebound thesis hinges on US surgeon education programs for new Ag+ technology, targeting surgical site infections. R&D spend rose 12% to £110 million, funding pipeline including bioengineered scaffolds for chronic ulcers.

Peers like Coloplast reported similar US softness but stronger pricing, highlighting ConvaTec's execution gap. Investors watch gross margins in this segment, which compressed to 52% from 55%, versus group average of 57%.

Infusion Care as Key Growth Engine

Infusion care's 38% surge underscores ConvaTec's diversification success. The 360 pump, launched 2024, features patented oscillation mimicking natural insulin delivery, reducing hypoglycemia risk by 30% per clinical data. US uptake accelerated via J-code reimbursement, enabling specialist billing.

Pipeline includes connected app integration for remote monitoring, positioning ConvaTec in digital health. At 10% of revenue, this segment boasts 70% gross margins, pulling up group profitability. Analysts project it reaching 15% mix by 2028, cushioning wound care volatility.

Competition from Tandem Diabetes and Insulet intensifies, but ConvaTec's affordability edge—pump priced 20% below peers—drives penetration in value-sensitive markets like Latin America.

Balance Sheet Strength Supports Capital Returns

Net debt stood at 1.7x EBITDA, down from 2.0x, post £150 million free cash generation. Pension deficit closed to £20 million via asset returns. Dividend yield of 7.5% at current LSE levels in GBP attracts income investors, with payout covered 2.1x by earnings.

£300 million share buyback authorized, with £100 million deployed since November 2025. M&A war chest of £500 million targets bolt-on deals in continence, like rumored US catheter maker. Leverage comfortably below 2.5x covenant.

Risks and Open Questions for US Investors

Key risks include prolonged US destocking, potential CMS reimbursement cuts to wound dressings under Medicare Part B reforms, and FX volatility with 30% revenue ex-UK/Europe. Pipeline delays in infusion software could cap growth, while generic erosion in legacy ostomy hits volumes.

Macro headwinds like US hospital staffing shortages slow procedure ramps. Valuation at 17x offers entry point versus peers, but consensus target of 260p implies 18% upside if US rebounds. Watch April US distributor surveys for leading indicators.

Geopolitical tensions in supply chains for rare gels pose inflation risk. ESG scrutiny rises on plastic pouch sustainability, with ConvaTec committing to 50% recycled materials by 2030.

Disclaimer: This is not investment advice. Stocks are volatile financial instruments.